DEA places narcolepsy drug oveporexton (Orzeyful) in schedule IV, effective November 12, 2026
Published November 15, 2026 · Coverage November 8–14, 2026, Pacific · Lower priority
The Drug Enforcement Administration (DEA) issued an interim final rule, published November 12, 2026, placing oveporexton, including its salts and isomers, in schedule IV of the Controlled Substances Act (CSA). The rule took effect November 12, 2026. Comments are due December 14, 2026. Anyone who handles oveporexton, other than a patient who possesses it under a lawful prescription, must hold a DEA registration, and registrants must apply schedule III to V security, inventory, recordkeeping and prescription requirements to it.
Background
The Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for narcolepsy type 1 in adults on August 5, 2026, and the Department of Health and Human Services (HHS) recommended schedule IV control.
Who this affects
Hospital and outpatient pharmacies, prescribers and any registrant that stocks, dispenses or prescribes oveporexton.
Why it matters
Hospitals that add oveporexton to the formulary must treat it as a controlled substance from November 12, 2026: secure storage, inventory, records, and prescriptions that meet the controlled-substance rules. The rule ties the initial inventory to the date a registrant first engages in handling controlled substances, with an inventory every two years after that. Separately, subsection (d) of 21 CFR 1304.11, the section the rule cites, requires every registrant that must keep records and possesses a newly scheduled substance on the effective date of the scheduling rule to take an inventory of all stocks of it on hand, so a hospital registrant that held oveporexton on November 12, 2026 must inventory those stocks as of that date. Inference: automated dispensing cabinet and electronic health record settings that do not flag it as schedule IV would produce recordkeeping gaps.
Required actions
- From November 12, 2026, handle oveporexton under schedule IV controls: DEA registration, schedule III to V security (21 CFR 1301.71 to 1301.77), inventory as the rule's inventory section describes it (an initial inventory when a registrant first engages in handling controlled substances, then an inventory every two years; and, for oveporexton already on hand on November 12, 2026, an inventory of those stocks as of that date under 21 CFR 1304.11(d)), records and reports, and prescriptions issued under 21 CFR part 1306 and part 1311, subpart C.
Recommended action
- Pharmacy: update the formulary, automated dispensing cabinet and electronic health record controlled-substance flags for oveporexton.
- Confirm that any oveporexton on hand on November 12, 2026 was inventoried as of that date and that the inventory is filed with the controlled-substance records.
Scope and timing
- Authority status
- Interim final
- Responsible owner
- Pharmacy
- Publication date
- 2026-11-12
- Effective date
- 2026-11-12
- Comment deadline
- 2026-12-14
- Other dates
- Hearing requests and waivers due 2026-12-14
Not established
Whether California has scheduled oveporexton under state law was not checked.
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →